GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulike Biological Engineering Inc (SHSE:603566) » Definitions » Debt-to-EBITDA

Pulike Biological Engineering (SHSE:603566) Debt-to-EBITDA : 0.02 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Pulike Biological Engineering Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pulike Biological Engineering's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1 Mil. Pulike Biological Engineering's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1 Mil. Pulike Biological Engineering's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥128 Mil. Pulike Biological Engineering's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pulike Biological Engineering's Debt-to-EBITDA or its related term are showing as below:

SHSE:603566' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.02   Max: 0.04
Current: 0.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of Pulike Biological Engineering was 0.04. The lowest was 0.01. And the median was 0.02.

SHSE:603566's Debt-to-EBITDA is ranked better than
99.64% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs SHSE:603566: 0.01

Pulike Biological Engineering Debt-to-EBITDA Historical Data

The historical data trend for Pulike Biological Engineering's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulike Biological Engineering Debt-to-EBITDA Chart

Pulike Biological Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.04 0.01

Pulike Biological Engineering Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.22 0.06 -0.12 0.02

Competitive Comparison of Pulike Biological Engineering's Debt-to-EBITDA

For the Biotechnology subindustry, Pulike Biological Engineering's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulike Biological Engineering's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pulike Biological Engineering's Debt-to-EBITDA falls into.



Pulike Biological Engineering Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pulike Biological Engineering's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.997 + 1.055) / 288.265
=0.01

Pulike Biological Engineering's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.997 + 1.055) / 127.656
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Pulike Biological Engineering  (SHSE:603566) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pulike Biological Engineering Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pulike Biological Engineering's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulike Biological Engineering (SHSE:603566) Business Description

Traded in Other Exchanges
N/A
Address
15th New governance, Henan Province, Luoyang, CHN, 471000
Pulike Biological Engineering Inc is engaged in the research and development and production and operation of veterinary drugs.
Executives
Sun Jin Zhong Director
Zhang Zhen Supervisors
Wang Zhu Yi Supervisors
Ma Sui Ying Director
Song Yong Jun Director
Hu Wei Director
Qiao Rong Cen senior management
Zhou Li Peng senior management
Tian Ke Gong senior management
Kang Du Li senior management
Zhao Rui senior management
Qin De Chao Director
Pei Lian Feng senior management
Zhang Li Chang Director
Zhang Xu Ke Director

Pulike Biological Engineering (SHSE:603566) Headlines

No Headlines